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Background. Evans syndrome (ES) is a chronic autoimmune disease characterized by autoimmune hemolytic anemia along with
immune thrombocytopenic purpura. Few case reports of ES in pregnancy have been published, and ES may be diﬃcult to
distinguish from other diagnoses more common in pregnancy. Guidelines for treatment of ES are not well-deﬁned. Case. A
23-year-old multigravid woman in active labor was found to have severe anemia and thrombocytopenia. She was
diagnosed with ES and started on immunosuppressive treatments for persistent immune thrombocytopenic purpura. In the
postpartum period, she was found to have coronavirus (COVID-19) infection and acute pulmonary embolism. Conclusion.
Evans syndrome is a challenge to diagnose in pregnancy and poses important considerations for intrapartum and postpartum
management.

1. Introduction

2. Case Presentation

Evans syndrome (ES) is a chronic autoimmune disease characterized by autoimmune hemolytic anemia (AIHA) with
immune thrombocytopenic purpura (ITP) [1]. Clinical features include pallor, weakness, fatigue, jaundice, petechiae,
ecchymosis, and epistaxis. Diagnosis is made by a positive
direct antiglobulin test (DAT) in the setting of hemolytic
anemia.
The incidence of ITP alone is 1-5 cases per 10,000 pregnancies [2]. Although the incidence of ES in pregnancy is
not well known, it has been diagnosed in 1.8%-10% of
patients with ITP. The majority of patients with ES have
onset in childhood, and 60%-70% of patients with ES are
women [1].
In pregnant patients with anemia and thrombocytopenia,
it is important to diﬀerentiate ES from causes that are more
common in pregnancy. We present a case report of a patient
with ES diagnosed during pregnancy, her clinical course,
treatments, and complications during the postpartum period.

A 23-year-old gravida 2, para 1, with no known medical history presented at 38 weeks of gestation with spontaneous
rupture of membranes, contractions, and blood-tinged discharge. She reported uncomplicated prenatal care; however,
no records could be obtained.
On admission, the patient’s vital signs were within normal limits. She was 8 cm dilated on the cervical exam. Due
to her desire for pain control, and in anticipation of expeditious delivery in a multiparous patient, anesthesia was
consulted for neuraxial analgesia. A review of her obstetric
history revealed a prior uncomplicated vaginal delivery at
38 weeks of gestation. Laboratory studies from that admission revealed hemoglobin of 12.5 g/dL and platelet count of
223 K/μL. She had no known history of thrombocytopenia,
so an epidural was placed prior to obtaining complete blood
count results, which was in accordance with hospital policy.
Laboratory testing (Table 1) resulted afterwards and was
notable for hemoglobin of 7.1 g/dL, hematocrit of 22.1%,
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Table 1: Initial laboratory values.

Laboratory test

Value

Hemoglobin

7.1 g/dL∗

Hematocrit

22.1%∗

Mean corpuscular volume

74.7 fL∗

Mean corpuscular hemoglobin concentration
Red blood cell distribution width

32.3 g/dL
18.1%∗

Platelets

<10 K/μL∗

White blood cell count
Prothrombin time
Partial thromboplastin time
International normalized ratio
Fibrinogen
Aspartate aminotransferase
Alanine aminotransferase
Total bilirubin
Direct bilirubin
Alkaline phosphatase

9.9 K/μL
12.6 seconds
27 seconds
0.98
388 mg/dL
16 IU/L
7 IU/L
0.8 mg/dL
0.1 mg/dL
296 IU/L∗

Lactate dehydrogenase

263 IU/L∗

Ferritin

17 ng/mL∗

D-dimer

2.63 μg/mL FEU∗

Iron
Iron saturation

45 μg/dL∗
10%∗

Folate

12.4 ng/mL∗

Vitamin B12

136 pg/mL∗

Total iron-binding capacity

448 μg/dL∗

Haptoglobin
Reticulocyte percent
Absolute reticulocyte count
∗

<30.0 mg/dL∗
6.0%∗
149.4 K/μL∗

Abnormal values.

mean corpuscular volume of 74.7 fL, and platelets of
<10 K/μL. Upon further questioning, the patient reported a
history of ecchymosis and an episode of epistaxis 2 weeks
prior. She reported no history of heavy menstrual bleeding,
hemarthrosis, or bleeding gums. On examination, no pallor,
ecchymosis, or organomegaly was detected. There was a concern for hemodilution of the blood sample due to the location
of the blood draw or laboratory error, so the blood was
redrawn.
While awaiting repeat laboratory results, the patient
delivered a male neonate by spontaneous vaginal delivery.
Neonatal laboratory studies were normal with a hemoglobin
of 18.8 g/dL and platelet count of 245 K/μL. Total quantitative blood loss during delivery was 400 mL. Epidural was
removed immediately post delivery. Subsequently, repeat
laboratory tests conﬁrmed the initial results, with hemoglobin of 5.6 g/dL, hematocrit of 17.7%, and platelets of
<10 K/μL. Further laboratory studies (Table 1) showed no
marked abnormalities in coagulation proﬁle or hepatic panel
results. Iron and B12 deﬁciencies were noted.

Peripheral blood smear (Figure 1) revealed microcytic
anemia with anisocytosis, polychromasia, and thrombocytopenia. Teardrop cells, reticulocytes, and small spherocytes
were present. No overt schistocytes or fragmentation of red
blood cells was noted. There was no concern for thrombotic
thrombocytopenic purpura.
Antibody screen was positive for warm autoantibodies.
DAT was positive for anti-immunoglobulin G and anticomplement antibodies. The diagnosis of ES was made based
on the positive DAT in the setting of hemolytic anemia.
Hematology was consulted, and transfusion of 2 units of
red blood cells and 1 pack of platelets was recommended. The
patient also received 1 gram of intravenous iron dextran. She
was treated with oral dexamethasone, 40 mg daily for 4 days,
with a subsequent rise in platelets to 55 K/μL (Figure 2). She
was discharged on postpartum day 4 with a plan for weekly
outpatient laboratory studies and oral prednisone (60 mg
daily). She was also started on folate (1 mg daily) and B12
(1000 mcg monthly) supplementation.
On postpartum day 9, follow-up laboratory studies
revealed a platelet count of <10 K/μL. The patient received
a second 4-day course of oral dexamethasone, 40 mg daily,
with a good response. Her platelet count rose to 55 K/μL.
On postpartum day 18, laboratory results showed the platelet
count decreased to 16 K/μL, and she received a third course
of dexamethasone, 20 mg daily for 4 days, and intravenous
immunoglobulin (IVIG), 1 mg/kg for 2 days. Repeat DAT
remained positive for warm autoantibodies. Given the poor
response to steroids, rituximab therapy was initiated. On
postpartum days 21 and 28, the patient received 2 doses of
rituximab (375 mg/m2 weekly).
On postpartum day 34, the patient presented to the emergency department with chest pain and shortness of breath.
The evaluation was notable for elevated D-dimer, and a computed tomography scan was obtained due to suspicion of pulmonary embolism. Imaging revealed ground-glass opacities
and an acute pulmonary embolism (Figure 3). Notably, lower
extremity dopplers during initial admission showed no
venous thromboses. The patient was started on anticoagulation with high-intensity heparin infusion. The patient
reported that her mother had tested positive for the recently
emerged novel coronavirus (COVID-19). Given her symptoms, sick contact status, and imaging ﬁndings, the patient
was tested for COVID-19. Nasopharyngeal specimen testing
for detection of the 2019 novel coronavirus ribonucleic
acid by real-time polymerase chain reaction was positive.
The platelet count on readmission was 131 K/μL and
remained stable over 200 K/μL. Rituximab infusion was
held for several weeks due to active COVID-19 infection
and stable platelet count.

3. Discussion
ES is an autoimmune disorder with autoantibodies against
red blood cells and platelets leading to the development of
AIHA and ITP. Diagnosis of ES in pregnancy must be diﬀerentiated from other conditions more commonly associated
with pregnancy. This patient’s clinical presentation and
laboratory studies were not suggestive of preeclampsia,
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Figure 1: Peripheral blood smear showing microcytic, slightly hypochromic anemia with anisocytosis and polychromasia,
thrombocytopenia, and slight leukocytosis. Teardrop cells, reticulocytes, and small spherocytes are present. No overt schistocytes,
fragmentation of red blood cells, overt dysplasia, or presence of blasts noted.

Dexamethasone administration
IVIG
Rituximab

Figure 2: Platelet and hemoglobin values over time. Times of therapy noted by colored arrows. Initial course of steroids with good response,
however subsequent decline in platelet count, requiring further treatment with additional steroids, IVIG, and rituximab. Abbreviations: IVIG:
intravenous immunoglobulin.

disseminated intravascular coagulation, or hemolysis, elevated liver enzymes, or low platelet count (HELLP) syndrome. Blood pressure, liver function tests, and coagulation
proﬁle on admission were normal. Gestational thrombocytopenia was thought to be unlikely due to the extremely low
platelet count.
In a literature search of cases of ES in pregnancy, a 2010
review article identiﬁed a total of 14 pregnancies, with data
available for 9 cases [2]. Case reports of an additional 5 cases
have since been published [2–5]. Of these 14 pregnancies for
which data is available, 5 were complicated by preeclampsia,
3 by postpartum hemorrhage, and 1 with placental abruption. Two pregnancies were associated with stillbirth, one of
these with a fetal intracranial subdural hematoma and the
other with an erythroblastic fetus. One neonate showed evidence of hemolysis 2 months postpartum that spontaneously
improved.

Guidelines for the treatment of ES are not well-deﬁned.
Steroids are often considered ﬁrst-line therapy, with the use
of IVIG in severe cases. Second-line therapies include immunosuppressive agents such as rituximab, mofetil mycophenolate, and cyclosporine. In the series of cases described above,
5 of 14 patients improved with steroid treatment exclusively
and 5 received IVIG. One patient underwent plasma
exchange in addition to immunosuppressive therapies and
5 ultimately underwent splenectomy. As with the patient
described in this case report, many of these cases demonstrated persistent relapsing ITP, while hemoglobin stabilized
early in presentation.
During intrapartum management of a patient with ES,
regional anesthesia must be managed carefully. According
to the “Practice Guidelines for Obstetric Anesthesia” published by the American Society of Anesthesiologists [6], routine evaluation of platelet count prior to epidural placement
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(a)

(b)

Figure 3: Computed tomography of the chest demonstrating diﬀuse ground-glass opacities (a) throughout both lungs, which can be seen with
COVID-19 pneumonia. Acute pulmonary emboli (b) identiﬁed in segmental branches of lingula and left inferior lobar pulmonary artery
extending into segmental branches of left lower lobe, with ﬁlling defect noted by red arrow.

is not necessary in healthy patients. This case reinforces the
need in urgent situations to balance the patient’s desires for
pain control with safety concerns. A targeted history to evaluate for thrombocytopenia, including explicit questions
about the history of easy bruising, may have prompted earlier
detection of thrombocytopenia prior to epidural placement
in this case. Alternatively, requiring at least one platelet count
level to have been recorded during the current pregnancy
may reduce the risk of undetected thrombocytopenia and
adverse events with epidural placement. A collaborative multidisciplinary approach including consultation with anesthesiology is needed to develop a hospital-wide protocol for the
preanesthesia evaluation.
The trigger for the onset of ES in this patient was unclear.
Cytokine activity in pregnancy may lead to increased autoimmunization against red blood cells [4], leading to higher rates
of AIHA in pregnancy. About half of patients with ES have
other immune disorders such as systemic lupus erythematosus, immunodeﬁciencies, or autoimmune lymphoproliferative disorders. These cases, referred to as secondary ES, may
be more responsive to treatment [7] than primary ES, which
is not associated with an underlying condition. At least one
case report of a patient with SARS-CoV-2 infection and
underlying immune dysregulation subsequently found to
have ES has been described [8]. The onset of this patient’s
COVID-19 infection was unknown; however, preexisting
COVID-19 infection leading to widespread immune activation prior to her initial admission may have served as a trigger for the new onset of ES. Her clinical course and robust
treatment response are also concordant with secondary ES.
Alternatively, the use of immunosuppressive therapies
including steroids and rituximab may have contributed to
her development of COVID-19 pneumonia. Further studies
are warranted to delineate the association of immunosuppressive agents used for ES with respiratory infections or
whether infection serves as a potential trigger for ES in
pregnancy.
Many autoimmune diseases, including warm AIHA, are
associated with an increased risk of venous thromboembolic

events. This risk is cited as 15%-33% [9] in warm AIHA.
Additionally, thromboembolic events may be associated with
IVIG, with added risk during pregnancy and the postpartum
period. The use of prophylactic anticoagulation after delivery
and systematic screening for venous thromboembolism in
patients with ES is an area that may beneﬁt from further
studies.
Lessons to be incorporated from this case include the
need to identify rare causes of anemia and thrombocytopenia
in pregnancy such as ES and diﬀerentiate these from other
causes more common in pregnancy. Intrapartum management of patients with ES highlights the need for the development of an institutional protocol for preanesthesia evaluation
in the obstetric setting, perhaps with targeted history taking
for signs of thrombocytopenia. In the postpartum period,
systematic VTE screening and prophylaxis protocols for
diseases associated with increased thrombotic risk may be
beneﬁcial.
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